The challenge of drug resistance in cancer treatment: a current overview

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

(2017) Mark E. Issa et al.   Clinical Epigenetics

Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells

(2016) Athanasia Pavlopoulou et al.   CANCER LETTERS

The cancer stem-cell signaling network and resistance to therapy

(2016) A. Carnero et al.   CANCER TREATMENT REVIEWS

The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible

(2016) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Prodding the Beast: Assessing the Impact of Treatment-Induced Metastasis

(2015) J. M. L. Ebos   CANCER RESEARCH

FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance

(2015) David Westover et al.   Molecular Cancer

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine

(2015) Sébastien Benzekry et al.   SEMINARS IN CANCER BIOLOGY

DNA repair mechanisms in cancer development and therapy

(2015) Alessandro Torgovnick et al.   Frontiers in Genetics

Drug resistance to targeted therapies: Déjà vu all over again

(2014) Floris H. Groenendijk et al.   Molecular Oncology

“Drug resistance associated membrane proteins”

(2014) Katy S. Sherlach et al.   Frontiers in Physiology

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

Targeted cancer therapy – Are the days of systemic chemotherapy numbered?

(2013) Won Duk Joo et al.   MATURITAS

Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia

(2012) T. Bhatla et al.   BLOOD

Intratumor Heterogeneity: Evolution through Space and Time

(2012) C. Swanton   CANCER RESEARCH

Epigenetic Resensitization to Platinum in Ovarian Cancer

(2012) D. Matei et al.   CANCER RESEARCH

Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

(2012) Roel H. Wilting et al.   DRUG RESISTANCE UPDATES

Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance

(2012) Suneet Shukla et al.   DRUG RESISTANCE UPDATES

Mechanisms of acquired resistance to targeted cancer therapies

(2012) Mark R Lackner et al.   Future Oncology

Clonal evolution in cancer

(2012) Mel Greaves et al.   NATURE

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling

(2012) C Zeller et al.   ONCOGENE

Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics

(2011) Alvin J.X. Lee et al.   BIOCHEMICAL PHARMACOLOGY

Antiangiogenic Agent Sunitinib Transiently Increases Tumor Oxygenation and Suppresses Cycling Hypoxia

(2011) S. Matsumoto et al.   CANCER RESEARCH

CpG islands and the regulation of transcription

(2011) A. M. Deaton et al.   GENES & DEVELOPMENT

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology

Judah Folkman, a pioneer in the study of angiogenesis

(2008) Domenico Ribatti   ANGIOGENESIS

Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents

(2008) Yuval Shaked et al.   CANCER CELL